Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

The Effect of Age in Patients with Triple Vessel CAD Undergoing PCI vs. Surgery

Original Title: Effects of Age and Sex on Clinical Outcomes after Percutaneous Coronary Intervention Relative to Coronary Artery Bypass Grafting in Patients with Triple Vessel Coronary Artery Disease. Reference: KyoheiYamaji et al. Circulation. 2016 Mar 23. [Epub ahead of print].

 

Sex and age are factors that are often considered in the daily practice to decide between PCI or surgery.

The multicenter CREDO-Kyoto trial included 25816 patients; 5651 (men n=3998 and women n=1653) had triple vessel CAD and were considered good candidates for revascularization both with PCI and CABG (PCI n=3,165 and CABG n=2,486).

Patients were divided in three groups according to age tertile: ≤65 years (n=1,972), 66-73 years (n=1,820), and ≥74 years (n=1,859).

There was an excess mortality risk in ≥74 year old patients undergoing PCI compared to those undergoing CABG (HR 1.40, CI 95% 1.10 to 1.79; p=0.006), whereas this risk was neutral for ≤65 year old patients (HR 1.05, CI 95% 0.73 to 1.53; p=0.78) and also neutral for the group between 66 and 73 years of age (HR 1.03, CI 95% 0.78 to 1.36; p=0.85).

The excess mortality risk in the PCI group was significant in men (HR 1.24, CI 95% 1.03 to 1.50; p=0.02) and tended to be significant in women (HR 1.34 IC 95% 0.98 a 1.84; p=0.07).

Conclusion
There was a significant association between age and mortality risk in ≥74 year old patients with triple vessel CAD undergoing PCI compared to those undergoing CABG. The risk was neutral in younger patients.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...